Trial Profile
SGLT2 inhibition with empagliflozin in patients with type 2 diabetes mellitus: Influences on left ventricular mass, function, and cardiac lipid content (EMPATROPHY)
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 20 May 2022
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms EMPATROPHY
- 20 Mar 2019 Status changed from suspended to discontinued.
- 27 Sep 2018 Status has been changed to suspended.
- 21 Jun 2018 Planned End Date changed from 1 Apr 2018 to 1 Apr 2019.